Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18215447 | 0.86 | HSD17B10 (0.47) | HSD17B10CYP1A2KMT2AGAAAPEX1 | |
| SCHEMBL18209306 | 0.86 | HSD17B10 (0.47) | HSD17B10CYP1A2KMT2AGAAAPEX1 | |
| SCHEMBL11363508 | 0.83 | HSD17B10 (0.47) | HSD17B10CYP1A2GAA | |
| SCHEMBL11358485 | 0.83 | HSD17B10 (0.47) | HSD17B10CYP1A2GAAAPEX1AKR1B1 | |
| SCHEMBL12214779 | 0.82 | CYP1A2 (0.51) | HSD17B10CYP1A2KMT2AGAAESR1 | |
| SCHEMBL11195319 | 0.80 | HSD17B10 (0.43) | HSD17B10CYP1A2KMT2AATM | |
| SCHEMBL11367277 | 0.80 | ATM (0.56) | HSD17B10CYP1A2ATM | |
| SCHEMBL18215418 | 0.79 | HSD17B10 (0.73) | HSD17B10CYP1A2GAA | |
| SCHEMBL18215470 | 0.79 | HSD17B10 (0.73) | HSD17B10CYP1A2GAA | |
| SCHEMBL31133079 | 0.79 | HSD17B10 (0.73) | HSD17B10CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079467-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| EP-2079467-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-2001844-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008054675-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, FFAR2, GPR65 | HSD17B10 139/4885CYP1A2 1067/4885KMT2A 2688/4885 |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | HSD17B10 104/4885CYP1A2 208/4885KMT2A 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.